filmov
tv
This Time, It’s Personal

Показать описание
The Fragility Fractures in Focus podcast series by UCB is TARGETED AT HEALTHCARE PROFESSIONALS with the intention of exploring scientific advancements and providing a platform for peer-to-peer discussion on the topic of osteoporosis. In this episode, “This Time, It’s Personal”, host, Cesar Libanati, Head of Medical External Affairs at UCB, welcomes Professor of Metabolic Bone Disease and Consultant Rheumatologist at NIHR Cambridge Biomedical Research Centre, University of Cambridge, Dr Ken Poole, to discuss how personalization of fracture risk assessment and osteoporosis management, supported by digital technology, has the potential to optimize outcomes for patients. You can find further information about the podcast series here: UCB rounds off the 2023 podcast series with the two bone health congresses - FFN & ASBMR | UCB This podcast is only for use by healthcare professionals.
This educational podcast has been fully sponsored by UCB and the content does not necessarily reflect the views of UCB. As a pharmaceutical company, UCB adheres to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice. Speaker Disclosures: Dr Ken Poole has received consulting fees, research or institutional support and/ or educational grants from UCB. For healthcare professionals only.Date of preparation: September 2023 l GL-DA-2300156© UCB Biopharma SRL, 2023. All rights reserved.
This educational podcast has been fully sponsored by UCB and the content does not necessarily reflect the views of UCB. As a pharmaceutical company, UCB adheres to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice. Speaker Disclosures: Dr Ken Poole has received consulting fees, research or institutional support and/ or educational grants from UCB. For healthcare professionals only.Date of preparation: September 2023 l GL-DA-2300156© UCB Biopharma SRL, 2023. All rights reserved.